Cedazuridine
Near Add Your Location
Accepting patients
Olutasidenib Combination Therapy
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
- IDH1 Inhibitor
- Phase 2